Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View PlansCash Conversion
0.57x
Novartis's operating cash flow covered 57% of net income in FY 2025. Some earnings may be tied up in working capital.
Free Cash Flow
₹745.70M
Novartis's free cash flow was ₹745.70M in FY 2025, down 34.2% from FY 2024.
Dividend Coverage
1.2x
Novartis's free cash flow covered dividends 1.2x in FY 2025 but leaves limited surplus.
CapEx Intensity
0.0%
Capital expenditure was 0.0% of operating cash flow in FY 2025 for Novartis, indicating a capital-light business.
Hover the chart icon for YoY change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 1.23B | 1.30B | |
| Cash flow Operating Activities | 1.13B | 745.70M | |
| Investments in PPE | 0 | 0 | |
| Cash flow Investing Activities | 331.30M | -33.10M | |
| Dividend Paid | -1.17B | -617.30M | |
| Cash flow Financing Activities | -1.21B | -641.50M | |
| Cash at beginning of period | 194.20M | 449.60M | |
| Cash at end of period | 449.60M | 520.70M | |
| Free Cash Flow | 1.13B | 745.70M |
Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025